1 |
Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study [J]. JAMA Oncol, 2017, 3(4): 524-548.
|
2 |
Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends--an update [J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 16-27.
|
3 |
El Yaagoubi OM, Oularbi L, Bouyahya A, et al. The role of the ubiquitin-proteasome pathway in skin cancer development: 26S proteasome-activated NF-κB signal transduction [J]. Cancer Biol Ther, 2021, 22(10-12): 479-492.
|
4 |
Storz P. Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy? [J]. Expert Rev Anticancer Ther, 2013, 13(5): 501-504.
|
5 |
Andela VB, Schwarz EM, O'Keefe RJ, et al. A genome-wide expression profile and system-level integration of nuclear factor kappa B regulated genes reveals fundamental metabolic adaptations during cell growth and survival [J]. FEBS Lett, 2005, 579(30): 6814-6820.
|
6 |
马李洁, 李莉娟, 张连生, 等. 多发性骨髓瘤治疗现状及前景 [J]. 临床荟萃, 2015, 30(4): 476-480
|
7 |
马勇, 汪兴洪. 多发性骨髓瘤治疗进展 [J]. 亚太传统医药, 2012, 8(4): 201-202.
|
8 |
Genin E, Reboud-Ravaux M, Vidal J. Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry [J]. Curr Top Med Chem, 2010, 10(3): 232-256.
|
9 |
邢志佳, 张叶叶, 马宇衡, 等. 针对 20S 蛋白酶体的抗肿瘤药物研究进展 [J]. 天津药学, 2015, 27(1): 55-57.
|
10 |
Liu L, Zhao N, Xu W, et al. Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma [J]. J Hematol Oncol, 2016, 9(1): 54.
|
11 |
Wang H, Guan F, Chen D, et al. An analysis of the safety profile of proteasome inhibitors for treating various cancers [J]. Expert Opin Drug Saf, 2014, 13(8): 1043-1054.
|
12 |
Lisa Z, Myriem B, Ross L, et al. Carflzomib potentiates CUDC-101-nduced apoptosis in anaplastic thyroid cancer [J]. Oncotarget, 2016, 7(13): 16517-16528.
|
13 |
Areeb Z, Stylli SS, Ware TM, et al. Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib [J]. Med Oncol, 2016, 33(5): 53.
|
14 |
Alanazi A, Algfeley SG, Al-Hosaini KA, et al. Therapeutic potential of carfilzomib, an irreversible proteasome inhibitor, against acetaminophen-induced hepatotoxicity in mice [J]. J Biochem Mol Toxicol, 2017, 31(4).
|
15 |
Jeon YJ, Khelifa S, Ratnikov B, et al. Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies [J]. Cancer Cell, 2015, 27(3): 354-369.
|
16 |
Li Y, Li J, Li S, et al. Curcumin attenuates glutamate neurotoxicity in the hippocampus by suppression of ER stress-associated TXNIP/NLRP3 inflammasome activation in a manner dependent on AMPK [J]. Toxicol Appl Pharmacol, 2015, 286(1): 53-63.
|
17 |
Høyer-Hansen M, Jäättelä M. Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium [J]. Cell Death Differ, 2007, 14(9): 1576-1582.
|
18 |
Ding WX, Ni HM, Gao W, et al. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability [J]. Am J Pathol, 2007, 171(2): 513-524.
|
19 |
Moretti L, Cha YI, Niermann KJ, et al. Switch between apoptosis and autophagy: radiation-induced endoplasmic reticulum stress?[J]. Cell Cycle, 2007, 6(7): 793-798.
|